

Interim Financial Statements (Un-audited)
For the Half Year Ended December 31, 2019




Beximco Pharmaceuticals Limited

Financial Statements- Consolidated


Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated Statement of Financial Position (Un-audited)
As at December 31, 2019

		As at December 31, 2019	Taka '000 As at June 30, 2019
ASSETS			
Non-Current Assets			
		36,721,861	35,949,931
Property, Plant and Equipment- Carrying Value	4	34,860,496	34,056,667
Intangible Assets		1,310,789	1,334,922
Goodwill		546,691	546,691
Other Investment	5	3,885	5,329
Other Non-current Assets		-	6,322
Current Assets			
		11,958,181	13,264,161
Inventories	6	5,471,403	5,924,031
Spares & Supplies		646,154	726,127
Accounts Receivable		3,080,861	3,334,959
Loans, Advances and Deposits	7	2,067,250	2,309,504
Advance Income Tax		-	35,681
Short Term Investment		195,580	323,365
Cash and Cash Equivalents	8	496,933	610,494
TOTAL ASSETS		48,680,042	49,214,092
SHAREHOLDERS' EQUITY AND LIABILITIES			
Equity Attributable to the Owners of the Company			
		30,684,957	29,588,317
Issued Share Capital		4,055,564	4,055,564
Share Premium		5,269,475	5,269,475
Excess of Issue Price over Face Value of GDRs		1,689,637	1,689,637
Capital Reserve on Merger		294,951	294,951
Revaluation Surplus		1,127,796	1,131,853
Unrealized Gain/(Loss)		1,060	2,504
Retained Earnings		18,246,474	17,144,333
Non-Controlling Interest		281,461	276,007
TOTAL EQUITY		30,966,418	29,864,324
Non-Current Liabilities			
		5,981,804	6,603,936
Long Term Borrowings-Net of Current Maturity	9 A	1,902,522	2,595,608
Liability for Gratuity and WPPF & Welfare Funds		1,927,484	1,860,905
Deferred Tax Liability		2,151,798	2,147,423
Current Liabilities and Provisions			
		11,731,820	12,745,832
Short Term Borrowings		7,396,947	9,272,501
Long Term Borrowings-Current Maturity	9 B	1,569,401	1,616,671
Creditors and Other Payables		1,058,797	1,091,810
Accrued Expenses		644,251	590,317
Dividend Payable		615,180	7,235
Income Tax Payable		447,244	167,298
TOTAL EQUITY AND LIABILITIES		48,680,042	49,214,092


A S F Rahman
Chairman


Salman F Rahman
Vice Chairman


Nazmul Hassan
Managing Director


Mohammad Ali Nawaz
Chief Financial Officer


Mohammad Asad Ullah, FCS
Executive Director & Company Secretary

Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated Statement of Profit or Loss and Other Comprehensive Income (Un-audited)
For the Period July 2019 - December 2019

		Taka '000			
	Notes	July - December 2019	July - December 2018	October- December 2019	October- December 2018
Net Revenue		12,495,526	11,109,798	6,192,191	5,724,672
Cost of Goods Sold	10	(6,687,655)	(5,939,756)	(3,325,974)	(3,084,613)
Gross Profit		5,807,871	5,170,042	2,866,217	2,640,059
Operating Expenses		(3,049,977)	(2,684,899)	(1,541,859)	(1,385,122)
Administrative Expenses	11	(388,704)	(365,072)	(200,227)	(200,770)
Selling, Marketing and Distribution Expenses	12	(2,661,273)	(2,319,827)	(1,341,632)	(1,184,352)
Profit from Operations		2,757,894	2,485,143	1,324,358	1,254,937
Other Income	13	156,792	30,531	96,672	10,011
Finance Cost		(532,325)	(482,180)	(228,287)	(253,363)
Profit Before Contribution to WPPF & Welfare Funds		2,382,361	2,033,494	1,192,743	1,011,585
Contribution to WPPF & Welfare Funds		(114,467)	(97,838)	(57,316)	(48,673)
Profit Before Tax		2,267,894	1,935,656	1,135,427	962,912
Income Tax Expenses		(532,521)	(448,434)	(269,929)	(229,406)
Current Tax		(528,146)	(489,153)	(257,488)	(236,325)
Deferred Tax Income/(Expense)	14	(4,375)	40,719	(12,441)	6,919
Profit After Tax		1,735,373	1,487,222	865,498	733,506
Profit/(Loss) Attributable to:					
Owners of the Company		1,726,446	1,488,403	861,686	733,472
Non-controlling interest		8,927	(1,181)	3,812	34
		1,735,373	1,487,222	865,498	733,506
Other Comprehensive Income-Unrealized Gain/(Loss)		(1,444)	(1,350)	(773)	(265)
Total Comprehensive Income for the Period		1,733,929	1,485,872	864,725	733,241
Total Comprehensive Income Attributable to:					
Owners of the Company		1,725,002	1,487,053	860,913	733,207
Non-controlling interest		8,927	(1,181)	3,812	34
		1,733,929	1,485,872	864,725	733,241
Earnings Per Share (EPS)	Tk.	4.26	3.67	2.12	1.81
Number of Shares Used to Compute EPS	Nos.	405,556,445	405,556,445	405,556,445	405,556,445




A S F Rahman
Chairman



Salman F Rahman
Vice Chairman



Nazmul Hassan
Managing Director



Mohammad Ali Nawaz
Chief Financial Officer



Mohammad Asad Ullah, FCS
Executive Director & Company Secretary

Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated Statement of Changes in Equity (Un-audited)
For the Period July 2019 -December 2019

As at December 31, 2019

Taka' 000

	Share Capital	Share Premium	Excess of Issue Price over Face Value of GDRs	Capital Reserve on Merger	Revaluation Surplus	Unrealized Gain/(Loss)	Retained Earnings	Equity attributable to the Owners of the Company	Non-Controlling Interests	Total Equity
Balance as on July 01, 2019	4,055,564	5,269,475	1,689,637	294,951	1,131,853	2,504	17,144,333	29,588,317	276,007	29,864,324
Total Comprehensive Income:										
Profit/(Loss) for the Period	-	-	-	-	-	-	1,726,446	1,726,446	8,927	1,735,373
Other Comprehensive Income/(Loss)	-	-	-	-	-	(1,444)	-	(1,444)	-	(1,444)
Cash Dividend	-	-	-	-	-	-	(608,335)	(608,335)	-	(608,335)
Cash Dividend NPL	-	-	-	-	-	-	(20,027)	(20,027)	(3,473)	(23,500)
Adjustment for Depreciation on Revalued Assets	-	-	-	-	(4,057)	-	4,057	-	-	-
Balance as on December 31, 2019	4,055,564	5,269,475	1,689,637	294,951	1,127,796	1,060	18,246,474	30,684,957	281,461	30,966,418
Number of Shares	405,556,445									
Net Asset Value (NAV) Per Share	75.66									

As at December 31, 2018

	Share Capital	Share Premium	Excess of Issue Price over Face Value of GDRs	Capital Reserve on Merger	Revaluation Surplus	Unrealized Gain/(Loss)	Retained Earnings	Equity attributable to the Owners of the Company	Non-Controlling Interests	Total Equity
Balance as on July 01, 2018	4,055,564	5,269,475	1,689,637	294,951	1,159,278	4,357	14,608,701	27,081,963	269,874	27,351,837
Total Comprehensive Income:										
Profit/(Loss) for the Period	-	-	-	-	-	-	1,488,403	1,488,403	(1,181)	1,487,222
Other Comprehensive Income/(Loss)	-	-	-	-	-	(1,350)	-	(1,350)	-	(1,350)
Cash Dividend	-	-	-	-	-	-	(506,945)	(506,945)	(868)	(507,813)
Adjustment for Depreciation on Revalued Assets	-	-	-	-	(4,588)	-	4,588	-	-	-
Adjustment for Deferred Tax on Revalued Assets	-	-	-	-	(19,396)	-	-	(19,396)	-	(19,396)
Balance as on December 31, 2018	4,055,564	5,269,475	1,689,637	294,951	1,135,294	3,007	15,594,747	28,042,675	267,825	28,310,500
Number of Shares	405,556,445									
Net Asset Value (NAV) Per Share	69.15									




A S F Rahman
Chairman



Salman F Rahman
Vice Chairman



Nazmul Hassan
Managing Director




Mohammad Ali Nawaz
Chief Financial Officer



Mohammad Asad Ullah, FCS
Executive Director & Company Secretary


Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated Statement of Cash Flows (Un-audited)
For the Period July 2019 - December 2019

		Taka '000	
	Note	July - December 2019	July - December 2018
Cash Flows from Operating Activities :			
Receipts from Customers and Others		12,970,054	10,864,946
Payments to Suppliers and Employees		(8,533,250)	(9,279,882)
Cash Generated from Operations		4,436,804	1,585,064
Interest Paid		(532,325)	(482,180)
Interest Received		15,547	18,132
Income Tax Paid		(212,520)	(267,848)
Net Cash Generated from Operating Activities	15	3,707,506	853,168
Cash Flows from Investing Activities :			
Acquisition of Property, Plant and Equipment		(1,309,616)	(876,834)
Intangible Assets		(13,065)	(10,604)
Investment in Subsidiary		-	(20,000)
Disposal of Property, Plant and Equipment		3,342	1,806
Dividend Received		20,027	-
(Increase)/Decrease in Short Term Investment		127,785	(17,230)
Net Cash Used in Investing Activities		(1,171,527)	(922,862)
Cash Flows from Financing Activities :			
Net Increase /(Decrease) in Long Term Borrowings		(750,702)	(654,507)
Net Increase/(Decrease) in Short Term Borrowings		(1,875,555)	831,186
Dividend Paid		(23,889)	(1,187)
Net Cash Used in Financing Activities		(2,650,146)	175,492
Increase/(Decrease) in Cash and Cash Equivalents		(114,167)	105,798
Cash and Cash Equivalents at Beginning of Period		610,494	393,736
Effect of exchange rate changes on Cash and Cash Equivalents		606	77
Cash and Cash Equivalents at End of Period	8	496,933	499,611
Net Operating Cash Flow Per Share		9.14	2.10
Number of Shares used to compute Net Operating Cash Flow Per Share		405,556,445	405,556,445


A S F Rahman
Chairman


Salman F Rahman
Vice Chairman


Nazmul Hassan
Managing Director


Mohammad Ali Nawaz
Chief Financial Officer


Mohammad Asad Ullah, FCS
Executive Director & Company Secretary

Beximco Pharmaceuticals Limited and its Subsidiaries
Selected Notes to the Financial Statements (Un-audited)
For the Period July 2019 - December 2019

1 Reporting Entity

1.1 About the Company

Beximco Pharmaceuticals Limited (BPL/ the Company) was incorporated as a public limited company in Bangladesh in 1976 and commenced its manufacturing operation in 1980. It is a leading manufacturer of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs). The Company was listed with Dhaka Stock Exchange in 1985 and with Chittagong Stock Exchange on its debut in 1995. In 2005, BPL took over Beximco Infusions Ltd., a listed company engaged in manufacturing and marketing of intravenous fluids and got enlisted with the Alternative Investment Market (AIM) of the London Stock Exchange through issuance of Global Depository Receipts (GDRs). In 2018, BPL acquired 85.22% shares of Nuvista Pharma Limited – a non-listed pharmaceutical company in Bangladesh specializing in hormones and steroid drugs and took over control of its management. Shares of the Company are traded in Dhaka and Chittagong Stock Exchanges of Bangladesh and its GDRs in AIM of the London Stock Exchange.

The registered office of the company is located at House No. 17, Road No. 2, Dhanmondi R/A, Dhaka. The industrial units are located at Tongi and Kaliakoir of Gazipur district – vicinities close to the capital city Dhaka. The manufacturing facilities of the Company are certified by leading global regulatory authorities including United States Food and Drug Administration (USFDA).

1.2 The Subsidiaries

Nuvista Pharma Limited (NPL)

Nuvista Pharma, formerly Organon (Bangladesh) Ltd., was a subsidiary of Netherlands based Organon International. It was originally incorporated as a private limited company. In 2006 the foreign holding of the company was sold out to Bangladeshi management and was renamed as Nuvista Pharma Limited. The Company through amendments to its memorandum of association in 2011 converted it into a public limited company. In April 2018, Beximco Pharmaceuticals Limited acquired majority shareholdings in Nuvista Pharma Limited (NPL) and through this acquisition BPL has become the immediate and ultimate parent of the company.

Beximco Pharma API Limited

Beximco Pharma API Limited was formed as a private limited company in December 2017 with a paid up capital of Taka 20 million divided into 2 million shares of Taka 10 each, fully held by BPL. The company intends to set up a facility at API Industrial Park to manufacture Active Pharmaceutical Ingredients (APIs) for domestic and international markets. The company is still in the initial phase of establishment.

1.3 Nature of Business

BPL is engaged in manufacturing and marketing of generic pharmaceuticals formulation products covering a wide range of therapeutic categories. It offers products in different dosage forms including Solid, Liquid, Cream and Ointment, Suppositories, Metered Dose Inhaler, Dry Powder Inhaler, Nasal Spray, Sterile, Lyophilized Injectable, Large Volume Intravenous Fluids. Besides formulation products BPL also manufactures Active Pharmaceutical Ingredients (APIs) and renders contract manufacturing services to other companies. Products of the company are sold in domestic and international markets.

NPL produces various pharmaceutical products including oral contraceptives, hormone, steroid, anti-histamine, anti-fibrinolytic, anti-infective, cardiac, gastrointestinal, musculoskeletal, respiratory, vitamin & mineral supplement and women's health products which are sold in the local market.

Both BPL and NPL provides contract manufacturing services.

2. Basis of Preparation of Financial Statements

These interim financial statements should be read in conjunction with the Financial Statements for the Year ended June 30, 2019 (hereafter referred to as the "Annual Financial Statements"), as they provide an update to previously reported information.

The accounting policies used are consistent with those used in the Annual Financial Statements. The financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRSs). The presentation of the Interim Financial Statements is consistent with the Annual Financial Statements. Where necessary, the comparatives have been reclassified or extended to take into account any presentational changes made in the Annual Financial Statements. The preparation of the Interim Financial Statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities at the date of the Interim Financial Statements. If in the future such estimates and assumptions, which are based on management's best judgment at the date of the Interim Financial Statements, deviate from the actual, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

3. Significant Accounting Policies

3.1 Basis of Consolidation

The financial statements of the subsidiaries-Nuvista Pharma Limited and Beximco Pharma API Limited, have been consolidated with those of Beximco Pharmaceuticals Limited in accordance with IFRS 10: Consolidated Financial Statements.

The Company acquired 85.22% shares of the issued paid up capital of Nuvista Pharma Limited. This ownership interest is adequate enough to establish control over NPL and thus BPL meets the conditions as stated in IFRS 10: Consolidated Financial Statements to consider NPL as a subsidiary.

Beximco Pharma API Limited (BPAL) was formed with a paid up capital of Tk.20,000,000 divided into 2,000,000 shares of Tk.10 each, all of which excepting 10 shares are held by Beximco Pharmaceuticals Ltd (BPL). Beximco Pharma API Ltd thus meets the conditions stated in IFRS 10: Consolidated Financial Statements to consider it as a subsidiary.

3.2 Inter-Company Transactions

Assets, Liabilities, Equity, Income, Expenses and Cash Flows arising out of transactions between the Company and the subsidiary have been eliminated in full in the Consolidated Financial Statements.

3.3. Non-Controlling Interests (NCIs)

Non-Controlling Interests (NCIs) at the date of acquisition has been measured at fair value of the net assets of the acquired company in proportion to the shares of the entitled holders. Profit or Loss and Other Comprehensive Income subsequent to the acquisition has been allocated to the Owners of the Company and to the NCIs and also disclosed in the financial statements.

3.4. Valuation of Goodwill

Goodwill has been determined in accordance with IFRS 3: Business Combination. This represents the excess of the aggregate of Purchase Consideration and the acquisition-date fair value of NCI's share in the net assets over the acquisition-date fair value of the net assets of the subsidiary.

3.5 Investment in Associates

Investment in Associates has been accounted for using the Equity method as per IAS 28: Investment in Associates and Joint Ventures.

	As at December 31, 2019	As at June 30, 2019
4. Property, Plant & Equipment - Carrying Value		
Land	4,067,829	4,067,830
Building and Other Constructions	7,822,270	7,820,306
Plant and Machinery	15,818,880	15,758,505
Furniture and Fixtures	324,878	314,395
Transport and Vehicle	1,148,526	1,144,902
Office Equipment	609,551	594,975
	29,791,934	29,700,913
Less :Accumulated Depreciation	(9,890,145)	(9,397,360)
Net Book Value	19,901,789	20,303,553
Capital Work in Progress	14,958,707	13,753,114
Carrying Value	34,860,496	34,056,667
5. Other Investment		
Bangladesh Export Import Co. Ltd.	2,316	3,760
Central Depository Bangladesh Ltd. (CDBL)	1,569	1,569
	3,885	5,329
6. Inventories		
Finished Goods	1,179,953	1,255,182
Raw and Packing Materials (Including Work in Process, Laboratory Chemicals, R & D Materials and Material in Transit)	4,205,668	4,583,713
Physician Sample	85,782	85,136
	5,471,403	5,924,031
7. Loans, Advances and Deposits		
Clearing & Forwarding	162,063	159,119
VAT	84,646	329,322
Claims Receivable	1,189	6,320
Security Deposit and Earnest Money	93,097	67,972
Lease Deposit	10,822	10,822
Capital Expenditure / Project	62,223	224,723
Bank Guarantee Margin	39,172	37,774
Advance against Salary	167,651	155,891
Motor Cycle	177,340	199,756
Raw & Packing Material	502,784	592,000
Overseas Liaison Office	40,309	35,318
Others	725,954	490,487
	2,067,250	2,309,504

	As at December 31, 2019	As at June 30, 2019
8. Cash and Cash Equivalents		
(a) Cash in Hand (Including Imprest Cash)	225,981	235,293
(b) Cash at Bank:		
(i) Current and FC Account	233,566	338,805
(ii) FDR Account	37,386	36,396
	496,933	610,494
9. Long Term Borrowings		
A. Net of Current Maturity		
Project Loan - ODDO BHF Aktiengesellschaft, Frankfurt, Germany	1,558,201	1,974,612
Obligation Under Finance Leases	200,251	247,375
AB Bank	129,232	330,410
Dhaka Bank Limited	14,838	43,211
	1,902,522	2,595,608
B. Current Maturity		
Project Loan - ODDO BHF Aktiengesellschaft, Frankfurt, Germany	864,176	860,105
Obligation Under Finance Leases	141,010	165,766
AB Bank	474,567	462,992
Dhaka Bank Limited	89,648	127,808
	1,569,401	1,616,671
C. Exchange fluctuation loss of Tk. 10,346,396 has been incurred on conversion of outstanding foreign currency loan to functional currency at the exchange rate prevailing on the date of Statement of Financial Position.		
	For the period July-December 2019	For the period July-December 2018
10. Cost of Goods Sold		
Materials	4,921,184	4,399,208
Factory Overhead	1,316,010	1,155,689
Depreciation	450,461	384,859
	6,687,655	5,939,756
11. Administrative Expenses		
Salary & Allowances	219,313	195,118
Repairs & Maintenance	25,521	22,627
Travelling & Conveyance	13,386	14,328
Company Secretarial, Regulatory Fee and AGM Expense	17,675	12,123
Depreciation	17,273	14,958
Security Expenses	4,622	4,700
Other Expenses	90,914	101,218
	388,704	365,072

	For the period July-December 2019	Taka '000 For the period July-December 2018
12. Selling, Marketing and Distribution Expenses		
Salary & Allowances	1,035,326	884,012
Travelling & Conveyance	300,270	253,629
Market Research & New Products	34,407	28,797
Sample, Literature & News Letter	314,379	292,482
Sales & Market Promotion Expenses	299,964	308,215
Distribution Commission	178,117	168,153
Delivery Expense	178,855	114,241
Depreciation and Amortization	71,901	71,721
Export Insurance, Freight and C & F Expenses	139,728	155,004
Security Expenses	8,922	9,020
Bad Debts	1,783	-
Other Expenses	97,621	34,553
	<u>2,661,273</u>	<u>2,319,827</u>
13. Other Income		
Interest Income	15,546	18,132
Cash Incentive on Export	49,822	-
Dividend Income	20,027	-
Royalty	77,825	19,412
Exchange Rate Fluctuation Gain/(loss)	(6,994)	(7,428)
Profit/(Loss) on Sale of Fixed Assets	(6)	79
Miscellaneous Income	572	336
	<u>156,792</u>	<u>30,531</u>
14. Deferred Tax Income/(Expense)		
Deferred Tax is arrived at as follows :		
Property, Plant & Equipment (Difference in book value & Tax base)	9,540,139	8,727,969
Deferred Liability (Gratuity)	(1,109,802)	(947,644)
Temporary Difference	8,430,337	7,780,325
Tax Rate		
Deferred Tax Liability at end of the period	2,140,385	1,977,302
Deferred Tax Liability at beginning of the period	2,118,775	1,998,625
Change in Deferred Tax Liability	21,610	(21,323)
Deferred Tax on Revaluation Surplus	(17,235)	(19,396)
Deferred Tax Income/(Expense)	<u>(4,375)</u>	<u>40,719</u>

For the period
July-December
2019

For the period
July-December
2018

15. Reconciliation of Net Profit with Cash Flows from Operating Activities

Profit after Tax	1,735,373	1,487,222
Adjustment to reconcile net profit to net cash Generated from Operating Activities :		
Non-cash Expenses :	610,589	730,571
Depreciation	502,437	434,342
Amortization	37,198	37,196
Gratuity & WPPF	66,579	299,752
Deferred tax	4,375	(40,719)
Non-operating items:	(10,281)	6,886
Loss on sale of Fixed Assets	6	(79)
Exchange rate fluctuation loss on Foreign Currency Bank Loan	10,346	7,042
Dividend Income	(20,027)	-
Effect of exchange rate changes on Cash and Cash Equivalents	(606)	(77)
Changes in working Capital	1,371,825	(1,371,510)
(Increase)/Decrease in Inventories	452,629	(1,231,756)
(Increase)/Decrease in Spares & Supplies	79,973	(27,353)
(Increase)/Decrease in Accounts Receivable	254,099	(288,839)
(Increase)/Decrease in Loans, Advances & Deposits	248,576	(153,263)
(Increase)/Decrease in Advance Income Tax	35,681	(405)
Increase/(Decrease) in Creditors and Other Payables	(33,013)	(175,926)
Increase/(Decrease) in Accrued Expenses	53,934	284,323
Increase/(Decrease) in Income Tax Payable	279,946	221,709
Net Cash Generated from Operating Activities	3,707,506	853,168




A S F Rahman
Chairman



Salman F Rahman
Vice Chairman



Nazmul Hassan
Managing Director



Mohammad Ali Nawaz
Chief Financial Officer



Mohammad Asad Ullah, FCS
Executive Director & Company Secretary

Financial Statements
Beximco Pharmaceuticals Stand-alone

Beximco Pharmaceuticals Limited
Statement of Financial Position (Un-audited)
As at December 31, 2019

Taka '000


ASSETS	Notes	As at December 31, 2019	As at June 30, 2019
Non-Current Assets		35,833,385	34,999,403
Property, Plant and Equipment- Carrying Value	3	33,053,899	32,209,440
Intangible Assets		601,089	610,122
Investment in Subsidiaries		2,145,186	2,145,186
Investment in Associates		29,326	29,326
Other Investment	4	3,885	5,329
Current Assets		11,490,472	12,793,493
Inventories	5	5,130,505	5,573,549
Spares & Supplies		636,548	715,341
Accounts Receivable		3,038,800	3,325,891
Loans, Advances and Deposits	6	2,020,255	2,273,041
Short Term Investment		195,580	323,365
Cash and Cash Equivalents	7	468,784	582,306
TOTAL ASSETS		47,323,857	47,792,896
EQUITY AND LIABILITIES			
Shareholders' Equity		30,666,366	29,600,843
Issued Share Capital		4,055,564	4,055,564
Share Premium		5,269,475	5,269,475
Excess of Issue Price over Face Value of GDRs		1,689,637	1,689,637
Capital Reserve on Merger		294,951	294,951
Revaluation Surplus		1,127,796	1,131,853
Unrealised Gain/(Loss)		1,060	2,504
Retained Earnings		18,227,883	17,156,859
Non-Current Liabilities		5,676,776	6,296,205
Long Term Borrowings-Net of Current Maturity	8 A	1,881,980	2,544,733
Liability for Gratuity and WPPF & Welfare Funds		1,786,452	1,748,901
Deferred Tax Liability		2,008,344	2,002,571
Current Liabilities and Provisions		10,980,715	11,895,848
Short Term Borrowings		6,933,686	8,701,025
Long Term Borrowings-Current Maturity	8 B	1,478,311	1,487,255
Creditors and Other Payables		1,026,463	1,037,089
Accrued Expenses		482,327	496,178
Dividend Payable		614,915	7,003
Income Tax Payable		445,013	167,298
TOTAL EQUITY AND LIABILITIES		47,323,857	47,792,896



A S F Rahman
Chairman



Salman F Rahman
Vice Chairman



Nazmul Hassan
Managing Director



Mohammad Ali Nawaz
Chief Financial Officer



Mohammad Asad Ullah, FCS
Executive Director & Company Secretary

Beximco Pharmaceuticals Limited
Statement of Profit or Loss and Other Comprehensive Income (Un-audited)
For the Period July 2019 - December 2019

	Notes	July - December 2019	July - December 2018	October- December 2019	October- December 2018
				Taka '000	
Net Sales Revenue		11,505,635	10,340,505	5,690,793	5,354,333
Cost of Goods Sold	9	(6,211,152)	(5,538,268)	(3,080,909)	(2,891,548)
Gross Profit		5,294,483	4,802,237	2,609,884	2,462,785
Operating Expenses		(2,745,976)	(2,411,601)	(1,379,867)	(1,258,978)
Administrative Expenses	10	(348,593)	(334,301)	(175,465)	(183,778)
Selling, Marketing and Distribution Expenses	11	(2,397,383)	(2,077,300)	(1,204,402)	(1,075,200)
Profit from Operations		2,548,507	2,390,636	1,230,017	1,203,807
Other Income		221,218	72,999	129,663	30,355
Finance Cost		(498,789)	(432,688)	(213,014)	(230,096)
Profit Before Contribution to WPPF & Welfare Funds		2,270,936	2,030,947	1,146,666	1,004,066
Contribution to WPPF & Welfare Funds		(108,140)	(96,712)	(54,603)	(47,813)
Profit Before Tax		2,162,796	1,934,235	1,092,063	956,253
Income Tax Expenses		(487,494)	(439,019)	(252,028)	(222,975)
Current Tax		(481,721)	(483,711)	(239,642)	(234,387)
Deferred Tax Income/(Expense)	13	(5,773)	44,692	(12,386)	11,412
Profit After Tax		1,675,302	1,495,216	840,035	733,278
Other Comprehensive Income-Unrealized Gain/(Loss)		(1,444)	(1,350)	(773)	(265)
Total Comprehensive Income		1,673,858	1,493,866	839,262	733,013

Earnings Per Share (EPS)	Tk.	4.13	3.69	2.07	1.81
Number of Shares Used to Compute EPS	Nos.	405,556,445	405,556,445	405,556,445	405,556,445




A S F Rahman
Chairman



Salman F Rahman
Vice Chairman



Nazmul Hassan
Managing Director



Mohammad Ali Nawaz
Chief Financial Officer



Mohammad Asad Ullah, FCS
Executive Director & Company Secretary

Beximco Pharmaceuticals Limited
Statement of Changes in Equity (Un-audited)
For the Period July 2019 - December 2019


As at December 31, 2019


Taka '000

	Share Capital	Share Premium	Excess of Issue Price over Face Value of GDRs	Capital Reserve on Merger	Revaluation Surplus	Unrealised Gain / (Loss)	Retained Earnings	Total	
Balance as on July 01, 2019	4,055,564	5,269,475	1,689,637	294,951	1,131,853	2,504	17,156,859	29,600,843	
Total Comprehensive Income :									
Profit for the Period	-	-	-	-	-	-	1,675,302	1,675,302	
Other Comprehensive Income / (Loss)	-	-	-	-	-	(1,444)	-	(1,444)	
Cash Dividend	-	-	-	-	-	-	(608,335)	(608,335)	
Adjustment for Depreciation on Revalued Assets	-	-	-	-	(4,057)	-	4,057	-	
Balance as on December 31, 2019	4,055,564	5,269,475	1,689,637	294,951	1,127,796	1,060	18,227,883	30,666,366	
Number of Shares								405,556,445	
Net Asset Value (NAV) Per Share								Tk.	75.62


As at December 31, 2018

	Share Capital	Share Premium	Excess of Issue Price over Face Value of GDRs	Capital Reserve on Merger	Revaluation Surplus	Unrealised Gain / (Loss)	Retained Earnings	Total	
Balance as on July 01, 2018	4,055,564	5,269,475	1,689,637	294,951	1,159,278	4,357	14,631,128	27,104,390	
Total Comprehensive Income for the period :									
Profit for the Period	-	-	-	-	-	-	1,495,216	1,495,216	
Other Comprehensive Income / (Loss)	-	-	-	-	-	(1,350)	-	(1,350)	
Cash Dividend	-	-	-	-	-	-	(506,945)	(506,945)	
Adjustment for Depreciation on Revalued Assets	-	-	-	-	(4,588)	-	4,588	-	
Adjustment for Deferred Tax on Revalued Assets	-	-	-	-	(19,396)	-	-	(19,396)	
Balance as on December 31, 2018	4,055,564	5,269,475	1,689,637	294,951	1,135,294	3,007	15,623,987	28,071,915	
Number of Shares								405,556,445	
Net Asset Value (NAV) Per Share								Tk.	69.22


A S F Rahman
Chairman


Salman F Rahman
Vice Chairman



Nazmul Hassan
Managing Director


Mohammad Ali Nawaz
Chief Financial Officer


Mohammad Asad Ullah, FCS
Executive Director & Company Secretary


Beximco Pharmaceuticals Limited
Statement of Cash Flows (Un-audited)
For the Period July 2019 - December 2019

	Note	July - December 2019	Taka '000 July - December 2018
Cash Flows from Operating Activities :			
Receipts from Customers and Others		11,988,110	10,085,325
Payments to Suppliers and Employees		(7,806,819)	(8,679,752)
Cash Generated from Operations		4,181,291	1,405,573
Interest Paid		(498,789)	(432,688)
Interest Received		15,547	18,132
Income Tax Paid		(204,007)	(262,002)
Net Cash Generated from Operating Activities	14	3,494,042	729,015
Cash Flows from Investing Activities :			
Acquisition of Property, Plant and Equipment		(1,296,454)	(849,146)
Intangible Assets		(13,065)	(10,604)
Acquisition of Subsidiary		-	(20,000)
Disposal of Property, Plant and Equipment		3,342	1,724
Dividend Received		20,027	-
(Increase)/Decrease in Short Term Investment		127,785	(17,230)
Net Cash Used in Investing Activities		(1,158,365)	(895,256)
Cash Flows from Financing Activities :			
Net Increase/(Decrease) in Long Term Borrowings		(682,043)	(597,851)
Net Increase/(Decrease) in Short Term Borrowings		(1,767,339)	871,116
Dividend Paid		(423)	(327)
Net Cash Used in Financing Activities		(2,449,805)	272,938
Increase / (Decrease) in Cash and Cash Equivalents		(114,128)	106,697
Cash and Cash Equivalents at Beginning of Period		582,306	369,109
Effect of exchange rate changes on Cash and Cash Equivalents		606	77
Cash and Cash Equivalents at End of Period	7	468,784	475,883
Net Operating Cash Flow Per Share		Tk. 8.62	1.80


A S F Rahman
Chairman


Salman F Rahman
Vice Chairman


Nazmul Hassan
Managing Director


Mohammad Ali Nawaz
Chief Financial Officer


Mohammad Asad Ullah, FCS
Executive Director & Company Secretary

Beximco Pharmaceuticals Limited
Selected Notes to the Financial Statements (Un-audited)
For the Period July 2019 - December 2019

1. Reporting Entity

1.1 About the company

Beximco Pharmaceuticals Limited (BPL/ the Company) was incorporated as a public limited company in Bangladesh in 1976 and commenced its manufacturing operation in 1980. It is a leading manufacturer of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs). The Company was listed with Dhaka Stock Exchange in 1985 and with Chittagong Stock Exchange on its debut in 1995. In 2005, BPL took over Beximco Infusions Ltd., a listed company engaged in manufacturing and marketing of intravenous fluids and got enlisted with the Alternative Investment Market (AIM) of the London Stock Exchange through issuance of Global Depository Receipts (GDRs). In 2018, BPL acquired 85.22% shares of Nuvista Pharma Limited – a non-listed pharmaceutical company in Bangladesh specializing in hormones and steroid drugs and took over control of its management. Shares of the Company are traded in Dhaka and Chittagong Stock Exchanges of Bangladesh and its GDRs in AIM of the London Stock Exchange.

The registered office of the company is located at House No. 17, Road No. 2, Dhanmondi R/A, Dhaka. The industrial units are located at Tongi and Kaliakoir of Gazipur district – vicinities close to the capital city Dhaka. The manufacturing facilities of the Company are certified by leading global regulatory authorities including United States Food and Drug Administration (USFDA).

1.2 Nature of Business

The company is engaged in manufacturing and marketing of generic pharmaceuticals formulation products covering a wide range of therapeutic categories. It offers products in different dosage forms including Solid, Liquid, Cream and Ointment, Suppositories, Metered Dose Inhaler, Dry Powder Inhaler, Nasal Spray, Sterile, Lyophilized Injectable, Large Volume Intravenous Fluids. Besides formulation products BPL also manufactures Active Pharmaceutical Ingredients (APIs) and renders contract manufacturing services to other companies. Products of the company are sold in domestic and international markets.

2. Basis of Preparation of Financial Statements

These interim financial statements should be read in conjunction with the Financial Statements for the Year ended June 30, 2019 (hereafter referred to as the "Annual Financial Statements"), as they provide an update to previously reported information.

The accounting policies used are consistent with those used in the Annual Financial Statements. The financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRSs). The presentation of the Interim Financial Statements is consistent with the Annual Financial Statements. Where necessary, the comparatives have been reclassified or extended to take into account any presentational changes made in the Annual Financial Statements. The preparation of the Interim Financial Statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities at the date of the Interim Financial Statements. If in the future such estimates and assumptions, which are based on management's best judgment at the date of the Interim Financial Statements, deviate from the actual, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

	As at December 31, 2019	As at June 30, 2019
		Taka '000
3. Property, Plant & Equipment- Carrying Value		
Land	3,343,741	3,343,741
Building and Other Constructions	7,499,762	7,497,797
Plant and Machinery	14,555,189	14,503,959
Furniture and Fixtures	277,351	267,441
Transport and Vehicle	1,004,397	998,626
Office Equipment	580,270	568,772
	27,260,710	27,180,336
Less :Accumulated Depreciation	(9,140,025)	(8,695,830)
Net Book Value	18,120,685	18,484,506
Capital Work in Progress	14,933,214	13,724,934
Carrying Value	33,053,899	32,209,440

	As at December 31, 2019	Taka '000 As at June 30, 2019
4. Other Investment		
Bangladesh Export Import Co. Ltd.	2,316	3,760
Central Depository Bangladesh Ltd. (CDBL)	1,569	1,569
	<u>3,885</u>	<u>5,329</u>
5. Inventories		
Finished Goods	1,073,945	1,155,804
Raw and Packing Materials (Including Work in Process, Laboratory Chemicals, R & D Materials and Material in Transit)	3,970,778	4,332,609
Physician Sample	85,782	85,136
	<u>5,130,505</u>	<u>5,573,549</u>
6. Loans, Advances and Deposits		
Clearing & Forwarding	162,063	159,119
VAT	59,672	306,316
Claims Receivable	1,189	6,320
Security Deposit and Earnest Money	88,132	62,559
Lease Deposit	10,822	10,822
Capital Expenditure / Project	62,223	224,723
Bank Guarantee Margin	39,172	37,774
Advance against Salary	159,845	152,574
Motor Cycle	177,340	199,756
Raw & Packing Material	502,784	592,000
Overseas Liaison Office	40,309	35,318
Others	716,704	485,760
	<u>2,020,255</u>	<u>2,273,041</u>
7. Cash and Cash Equivalents		
(a) Cash in Hand (Including Imprest Cash)	225,588	235,176
(b) Cash at Bank:		
(i) Current and FC Account	205,810	310,734
(ii) FDR Account	37,386	36,396
	<u>468,784</u>	<u>582,306</u>
8. Long Term Borrowings		
A. Net of Current Maturity		
Project Loan - ODDO BHF Aktiengesellschaft, Frankfurt, Germany	1,558,201	1,974,612
Obligation Under Finance Leases	194,547	239,711
AB Bank	129,232	330,410
	<u>1,881,980</u>	<u>2,544,733</u>
B. Current Maturity		
Project Loan - ODDO BHF Aktiengesellschaft, Frankfurt, Germany	864,176	860,105
Obligation Under Finance Leases	139,568	164,158
AB Bank	474,567	462,992
	<u>1,478,311</u>	<u>1,487,255</u>

C.Exchange fluctuation loss of Tk. 10,346,396 has been incurred on conversion of outstanding foreign currency loan to functional currency at the exchange rate prevailing on the date of Statement of Financial Position.

Taka '000

	For the Period July - December 2019	For the Period July - December 2018
9. Cost of Goods Sold		
Materials	4,683,280	4,191,428
Factory Overhead	1,121,842	1,003,914
Depreciation	406,030	342,926
	<u>6,211,152</u>	<u>5,538,268</u>
10. Administrative Expenses		
Salary & Allowances	193,322	175,929
Repairs & Maintenance	23,261	20,846
Travelling & Conveyance	13,067	14,169
Company Secretarial, Regulatory Fee and AGM Expense	17,045	11,743
Depreciation	15,703	13,262
Security Expenses	4,622	4,700
Other Expenses	81,573	93,652
	<u>348,593</u>	<u>334,301</u>
11. Selling, Marketing and Distribution Expenses		
Salary & Allowances	902,784	768,733
Travelling & Conveyance	264,019	223,066
Market Research & New Products	34,407	28,797
Sample, Literature & News Letter	286,863	269,469
Sales & Market Promotion Expenses	266,630	231,725
Distribution Commission	178,117	168,153
Delivery Expense	178,855	114,241
Depreciation and Amortization	49,017	44,831
Export Insurance, Freight and C & F Expenses	139,728	155,004
Security Expenses	8,922	9,020
Bad Debts	1,783	-
Other Expenses	86,258	64,261
	<u>2,397,383</u>	<u>2,077,300</u>
12. Other Income		
Interest Income	15,546	18,132
Distribution Commission	53,928	42,812
Cash Incentive on Export	49,822	-
Dividend Income	20,027	-
Royalty	88,889	19,412
Exchange Rate Fluctuation Gain/(loss)	(6,994)	(7,428)
Profit/(Loss) on Sale of Fixed Assets	-	71
	<u>221,218</u>	<u>72,999</u>

Taka '000

For the Period
July - December 2019For the Period
July - December 2018**13 Deferred Tax Income/(Expense)**

Deferred Tax is arrived at as follows :

Property, Plant & Equipment (Difference in book value & Tax base)	9,097,753	8,306,431
Deferred Liability (Gratuity)	(995,435)	(848,319)
Temporary Difference	8,102,318	7,458,112
Tax Rate	25%	25%
Deferred Tax Liability at end of the period	2,025,579	1,864,528
Deferred Tax Liability at beginning of the period	2,002,571	1,889,824
Change in Deferred Tax Liability	23,008	(25,296)
Deferred Tax on Revaluation Surplus	(17,235)	(19,396)
Deferred Tax Income/(Expense)	(5,773)	44,692

14 Reconciliation of Net Profit with Cash Flows from Operating Activities

Profit after Tax	1,675,302	1,495,216
-------------------------	------------------	------------------

Adjustment to reconcile net profit to net cash Generated from Operating Activities :

Non-cash Expenses :	514,074	653,819
Depreciation	448,652	378,923
Amortization	22,098	22,096
Gratuity & WPPF	37,551	297,492
Deferred Tax	5,773	(44,692)

Non-operating items:	(10,287)	6,894
Exchange rate fluctuation loss on Foreign Currency Bank Loan	10,346	7,042
Loss /(Gain) on sale of Fixed Assets	-	(71)
Dividend Income	(20,027)	-
Effect of exchange rate changes on Cash and Cash Equivalents	(606)	(77)

Changes in Working Capital	1,314,952	(1,426,914)
(Increase)/Decrease in Inventories	443,044	(1,268,201)
(Increase)/Decrease in Spares & Supplies	78,793	(28,602)
(Increase)/Decrease in Accounts Receivable	287,091	(316,941)
(Increase)/Decrease in Loans, Advances & Deposits	252,786	(141,640)
Increase/(Decrease) in Creditors and Other Payables	(10,626)	(134,844)
Increase/(Decrease) in Accrued Expenses	(13,851)	241,605
Increase/(Decrease) in Income Tax Payable	277,715	221,709

Net cash Generated from Operating Activities	3,494,042	729,015
---	------------------	----------------




A S F Rahman
Chairman



Salman F Rahman
Vice Chairman



Nazmul Hassan
Managing Director



Mohammad Ali Nawaz
Chief Financial Officer



Mohammad Asad Ullah, FCS
Executive Director & Company Secretary